Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials.

MLA

Tsoi, Kelvin Kf, et al. “Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer’s Disease: A Network Meta-Analysis of 76 Randomized Controlled Trials.” Clinical Pharmacology and Therapeutics, vol. 105, no. 1, Jan. 2019, pp. 121–30. EBSCOhost, https://doi.org/10.1002/cpt.1104.

APA

Tsoi, K. K., Chan, J. Y., Chan, F. C., Hirai, H. W., Kwok, T. C., & Wong, S. Y. (2019). Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer’s Disease: A Network Meta-analysis of 76 Randomized Controlled Trials. Clinical Pharmacology and Therapeutics, 105(1), 121–130. https://doi.org/10.1002/cpt.1104

Chicago

Tsoi, Kelvin Kf, Joyce Yc Chan, Felix Ch Chan, Hoyee W Hirai, Timothy Cy Kwok, and Samuel Ys Wong. 2019. “Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer’s Disease: A Network Meta-Analysis of 76 Randomized Controlled Trials.” Clinical Pharmacology and Therapeutics 105 (1): 121–30. doi:10.1002/cpt.1104.